Injectable L-Carnitine: Clinical Benefits, Mechanisms, and Modern Uses

Injectable L-carnitine is growing in popularity for fat loss, weight management, muscle recovery, athletic performance, and metabolic support.
Quick Take: NAD+

One of the most widely promoted benefits of NAD+ supplements is their potential to increase energy and improve physical performance.
Thymosin Alpha‑1: The Immune Peptide Powering the Next Wave of Precision Medicine

Thymosin Alpha‑1 (Ta1) is capturing global attention among researchers and clinicians for its immune‑balancing, anti‑inflammatory, and survival‑boosting capabilities across conditions ranging from sepsis to cancer. Cutting‑edge clinical data now sheds new light on when and where this peptide truly shines.
Quick Take: Melanotan I

Clinical studies reveal Melanotan 1’s potent synergistic action with UV light.
KPV Peptide: An Exciting Frontier in Anti-Inflammatory Research

Novaglo Research 15 October, 2025 The Big Picture: KPV (Lysine-Proline-Valine) is a naturally occurring three-amino-acid peptide showing remarkable anti-inflammatory properties in laboratory and animal studies. While human clinical trials haven’t been conducted yet, the preclinical research reveals fascinating mechanisms and promising therapeutic potential, particularly for inflammatory bowel disease. What Is KPV? KPV is a tripeptide—a remarkably […]
Quick Take: BPC 157 & TB 500 – The Most Researched Stack Ever?

Stacking BPC-157 with TB-500 may offer synergistic and complementary tissue regeneration effects by leveraging local and systemic healing mechanisms shown in preclinical medical studies.
BAM 15 – A new way to decrease body fat?

Novaglo Research 1 Oct 2025 Obesity is a health problem affecting more than 40% of US adults and 13% of the global population. Anti-obesity treatments including diet, exercise, surgery and pharmacotherapies have so far failed to reverse obesity incidence. Herein, we target obesity with a pharmacotherapeutic approach that decreases caloric efficiency by mitochondrial uncoupling. We […]
